China Xiaokang.com, April 2nd. Lao Malaysia Many countries and regions around the world are launching large-scale vaccination plans, and reports on the side effects of vaccines are gradually entering the public eye. At the same time, some teams began to study the new crown mixed vaccine to solve the current vaccine protection and supply shortages.
Hong Kong citizens are vaccinated against the new crown
The British Broadcasting Corporation BBC reported that at the end of March The University of Hong Kong said it plans to recruit volunteers to vaccinate two different technology platforms for research purposes. The leader of the study, the Hong Kong New Coronary Vaccine Clinical Events Evaluation Expert Committee, jointly convened Kong Fanyi, said that the level of antibody caused by mixed vaccination may be higher than that of single vaccination.
Among several vaccines currently being promoted globally, Phase III clinical data of Pfizer/BioNTech, Modena vaccine and Russia’s'Satellite V'vaccine show that its effectiveness is more than 90%; Oxford/ AstraZeneca The effective rate of vaccine is 62%-90%.
The vaccine effective rate of China National Pharmaceutical Group vaccinated in China is 79%. Phase III clinical data of the single-dose vaccine Ad5-nCoV developed by the Chinese military show that the overall effective rate is 65.7%; Kexing vaccine vaccinated in Hong Kong There are no Phase III clinical data.
The University of Hong Kong will study whether vaccination with different technology platforms will increase protection. The goal is to recruit one hundred healthy citizens between 18 and 60 years old to participate. They will be given a dose of Fubitai first, 28 days apart, and then a dose of Coxing vaccine, and then they will be given two doses of the same group and the same age but two doses. Comparison of people with a single platform vaccine.
Kong Fanyi said: "First, Fubitai will be given, and then the second dose will be given to inactivated vaccine. Because different immune systems are stimulated, the final antibody concentration is higher than that of vaccines inoculated with the same platform. Inactivated vaccines The immune system stimulation is relatively narrow, and most rely on neutralizing antibody stimulation. The cell-mediated immune system stimulation is relatively low because it is relatively narrow. If the narrower is injected first, the antibody production may not be so in the order of injecting the wider. high.
He believes that the two new coronavirus vaccines are safe. As long as there is no history of long-term illness or severe allergies, there is no special risk of mixed vaccination. At present, influenza vaccines will be given in a mixed platform.
.
